Kendall Capital Management Buys Shares of 7,395 ANI Pharmaceuticals, Inc. $ANIP

Posted by Geri Gentry on Aug 23rd, 2026

Kendall Capital Management purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 7,395 shares of the specialty pharmaceutical company’s stock, valued at approximately $612,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Elevation Point Wealth Partners LLC bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at $300,000. Quantbot Technologies LP bought a new position in ANI Pharmaceuticals in the 2nd quarter worth $505,000. Emerald Investment Advisers LLC bought a new position in ANI Pharmaceuticals in the 2nd quarter worth $5,786,000. William Blair Investment Management LLC bought a new position in ANI Pharmaceuticals in the 2nd quarter worth $21,372,000. Finally, NFJ Investment Group LLC purchased a new position in ANI Pharmaceuticals during the second quarter valued at $2,766,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Ori Gutwerg sold 3,162 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $77.00, for a total value of $243,474.00. Following the transaction, the senior vice president directly owned 75,534 shares of the company’s stock, valued at approximately $5,816,118. The trade was a 4.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thomas Haughey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.88, for a total value of $161,760.00. Following the completion of the transaction, the director owned 38,878 shares of the company’s stock, valued at $3,144,452.64. The trade was a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 18,987 shares of company stock worth $1,546,405. Company insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Trading Down 2.5%

Shares of ANI Pharmaceuticals stock opened at $75.35 on Friday. The company has a market capitalization of $1.73 billion, a P/E ratio of 16.24 and a beta of 0.44. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The company has a fifty day moving average of $80.36 and a 200 day moving average of $78.88. ANI Pharmaceuticals, Inc. has a fifty-two week low of $70.15 and a fifty-two week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same quarter in the prior year, the business posted $1.80 EPS. ANI Pharmaceuticals’s revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ANIP. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Guggenheim decreased their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Weiss Ratings downgraded ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Finally, Canaccord Genuity Group reduced their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $105.83.

Get Our Latest Analysis on ANIP

ANI Pharmaceuticals Profile

(Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.